Companies: 10,795·Total market cap: $144.5T
Estrella Immunopharma, Inc.

Estrella Immunopharma, Inc.

ESLANASDAQHealthcare● Active
$1.11
$-0.02(-1.77%)
Market Cap$47767962
P/E Ratio
52W High$3.15
52W Low$0.78

Estrella Immunopharma, Inc. (ESLA) Revenue

Annual & quarterly revenue history · segment & region breakdown

ESLA · revenue · updated Jun 9, 2026

Core revenue metrics

Estrella Immunopharma, Inc. trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from — in FY.

TTM revenue
$0.00B
4-quarter sum · USD
YoY growth
+0.00%
vs FY
Price / sales
mktCap ÷ TTM rev
Revenue per day
Est. TTM ÷ 365
Revenue / employee
$0K
3 employees
FY
FY
5Y CAGR
Fiscal year end
Dec 31
Currency
USD · GAAP
Filing
10-K / 10-Q
Source: FMP · Estrella Immunopharma, Inc. SEC filings · GAAPUpdated: 2026-06-09

Revenue trend

· Annual
YoY revenue growth %
revenue trend · revenue chart · revenue by year · revenue history

Revenue history

Fiscal year endRevenueChangeGrowth
ESLA revenue by year · ESLA revenue history · ESLA annual revenue data

About Revenue & Reporting

Revenue (also called sales, net sales, or turnover) is the total income Estrella Immunopharma, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.

Estrella Immunopharma, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.

Data sourced from Estrella Immunopharma, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.

Figures tie to SEC 10-K/10-Q and FMP income-statement endpoints where noted.

Frequently asked questions

ESLA revenue · 4 questions

ESLA's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from — in FY.

ESLA revenueESLA annual revenuewhat is ESLA revenueESLA TTM revenue

Source: FMP · Estrella Immunopharma, Inc. SEC filings · GAAP · Estrella Immunopharma, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026